These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 22809456

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP.
    J Med Chem; 2012 Feb 09; 55(3):1318-33. PubMed ID: 22196621
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J, Lin S, Myers RW, Trujillo ME, Pachanski MJ, Malkani S, Chen HS, Chen Z, Campbell B, Eiermann GJ, Elowe N, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, McMasters DR, Mitra K, Tong X, Xu L, Zhang F, Zhang R, Addona GH, Berger JP, Zhang B, Parmee ER.
    Bioorg Med Chem Lett; 2017 May 01; 27(9):2063-2068. PubMed ID: 28284809
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
    Zhi J, Zhai S.
    J Clin Pharmacol; 2016 Feb 01; 56(2):231-8. PubMed ID: 26183686
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP.
    Mol Pharmacol; 2011 Dec 01; 80(6):1156-65. PubMed ID: 21937665
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.
    Pike KG, Allen JV, Caulkett PW, Clarke DS, Donald CS, Fenwick ML, Johnson KM, Johnstone C, McKerrecher D, Rayner JW, Walker RP, Wilson I.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3467-70. PubMed ID: 21515051
    [Abstract] [Full Text] [Related]

  • 14. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M.
    Drug Discov Today; 2009 Aug 01; 14(15-16):784-92. PubMed ID: 19520181
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro.
    Wu GZ, Hong G, Zhang WP, Zhang HB.
    Arzneimittelforschung; 2009 Aug 01; 59(11):550-6. PubMed ID: 20066963
    [Abstract] [Full Text] [Related]

  • 17. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
    Deshpande AM, Bhuniya D, De S, Dave B, Vyavahare VP, Kurhade SH, Kandalkar SR, Naik KP, Kobal BS, Kaduskar RD, Basu S, Jain V, Patil P, Chaturvedi Joshi S, Bhat G, Raje AA, Reddy S, Gundu J, Madgula V, Tambe S, Shitole P, Umrani D, Chugh A, Palle VP, Mookhtiar KA.
    Eur J Med Chem; 2017 Jun 16; 133():268-286. PubMed ID: 28390958
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF.
    Science; 2003 Jul 18; 301(5631):370-3. PubMed ID: 12869762
    [Abstract] [Full Text] [Related]

  • 20. Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
    Park K.
    Arch Pharm Res; 2012 Dec 18; 35(12):2029-33. PubMed ID: 23263798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.